Date: 2018-10-03
Type of information: Licensing agreement
Compound: GSK3352589, GSK3008356, GSK3183475 and two undisclosed preclinical programs
Company: Boston Pharmaceuticals (USA - MA) GSK (UK)
Therapeutic area: Autoimmune diseases - Dermatological diseases - Digestive Diseases - Inflammatory diseases
Type agreement: licensing
Action mechanism:
- RET inhibitor/tyrosine kinase inhibitor/Diglyceride Acyltranferase (DGAT) 1 inhibitor/bromodomain inhibitor.
- GSK3352589 is a novel small molecule inhibitor of REarranged during Transfection (RET) tyrosine kinase which has completed Phase 1 studies and will be developed for the treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D).
- GSK3008356 is a potent and selective small molecule inhibitor of Diglyceride Acyltranferase (DGAT) 1 which has completed Phase 1 studies and has application as a treatment for acne.
- GSK3183475 is a novel small molecule inhibitor of Bromodomain and Extra-Terminal, Second Bromodomain (BET BD2) which as a topical formulation has therapeutic potential to treat vitiligo and/or psoriasis and is Phase 1-ready.
Disease: acne, irritable bowel syndrome with diarrhea (IBS-D)
Details:
- • On October 3, 2018, Boston Pharmaceuticals announced that it has in-licensed a portfolio of five early development programs from GSK. The portfolio includes two Phase 2-ready development candidates, one Phase 1-ready development candidate and two undisclosed preclinical programs with identified lead candidates. Boston Pharmaceuticals will assume full responsibility from GSK to progress the clinical stage programs for GSK3352589 which has completed Phase 1 studies and will be developed for the treatment of Irritable
Bowel Syndrome with Diarrhea (IBS-D); GSK3008356 which has completed Phase 1 studies and has application as a treatment for acne and GSK3183475 which as a topical formulation has therapeutic potential to treat vitiligo and/or psoriasis and is Phase 1-ready.
- The two undisclosed preclinical programs have specific lead candidates that are ready for IND-enabling studies. These programs target therapeutic areas that do not overlap with the clinical stage assets.
Financial terms:
- Financial terms of the transaction were not disclosed.
Latest news:
Is general: Yes
